Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
$315m Buy Off The Cards
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
You may also be interested in...
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
Data have shown that the Finnish firm's bexmarilimab has the potential to be the first macrophage immune checkpoint therapy and big pharma are getting interested in a licensing deal.